Synonym
MDL-26479; MDL 26479; MDL26479; Suritozole
IUPAC/Chemical Name
2,4-Dihydro-2,4-dimethyl-5-(3-fluorophenyl)-3H-1,2,4-triazole-3-thione
InChi Key
IWDUZEHNLHFBRZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H10FN3S/c1-13-9(12-14(2)10(13)15)7-4-3-5-8(11)6-7/h3-6H,1-2H3
SMILES Code
S=C1N(C)N=C(C2=CC=CC(F)=C2)N1C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
223.27
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava VO, Weir SJ. Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers. Biopharm Drug Dispos. 1997 May;18(4):325-34. PubMed PMID: 9158880.
2: O'Dell DM, Hamm RJ. Chronic postinjury administration of MDL 26,479 (Suritozole), a negative modulator at the GABAA receptor, and cognitive impairment in rats following traumatic brain injury. J Neurosurg. 1995 Nov;83(5):878-83. PubMed PMID: 7472558.
3: Dudchenko P, Gordon BM, Sarter M. Effects of benzodiazepine receptor ligands on simultaneous visual discriminations of variable difficulty. J Psychopharmacol. 1994 Jan;8(3):141-7. doi: 10.1177/026988119400800301. PubMed PMID: 22298580.
4: Holley LA, Miller JA, Chmielewski PA, Dudchenko P, Sarter M. Interactions between the effects of basal forebrain lesions and chronic treatment with MDL 26,479 on learning and markers of cholinergic transmission. Brain Res. 1993 May 7;610(2):181-93. PubMed PMID: 8391369.
5: Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM. MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties. Br J Pharmacol. 1992 Sep;107(1):78-86. PubMed PMID: 1330168; PubMed Central PMCID: PMC1907590.
6: Moran PM, Kane JM, Moser PC. Enhancement of working memory performance in the rat by MDL 26,479, a novel compound with activity at the GABAA receptor complex. Brain Res. 1992 Jan 8;569(1):156-8. PubMed PMID: 1319259.
7: Holley LA, Dudchenko P, Sarter M. Attenuation of muscarinic receptor blockade-induced impairment of spatial delayed alternation performance by the triazole MDL 26,479. Psychopharmacology (Berl). 1992;109(1-2):223-30. PubMed PMID: 1365661.
8: Sorensen SM, Zwolshen JM, Kane JM. The effects of a potential antidepressant, 2,4-dimethyl-5-(3-fluorophenyl)-3H-1,2,4-triazole-3-thione, in an electrophysiological model responsive to desipramine. Neuropharmacology. 1990 Jun;29(6):555-60. PubMed PMID: 2385327.
